Amarin Co. plc (NASDAQ:AMRN) – Equities researchers at Jefferies Group dropped their FY2020 earnings per share (EPS) estimates for Amarin in a research report issued to clients and investors on Tuesday. Jefferies Group analyst M. Andrews now anticipates that the biopharmaceutical company will post earnings of $0.06 per share for the year, down from their prior forecast of $0.07. Jefferies Group also issued estimates for Amarin’s FY2021 earnings at $0.15 EPS and FY2022 earnings at $0.35 EPS.
A number of other analysts have also weighed in on the stock. Cantor Fitzgerald set a $10.00 price target on shares of Amarin and gave the company a “buy” rating in a report on Wednesday, December 13th. ValuEngine lowered shares of Amarin from a “hold” rating to a “sell” rating in a report on Thursday, November 16th. Zacks Investment Research lowered shares of Amarin from a “hold” rating to a “sell” rating in a report on Tuesday, December 12th. BidaskClub raised shares of Amarin from a “hold” rating to a “buy” rating in a report on Friday, December 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Amarin in a report on Thursday, November 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $7.75.
In other Amarin news, insider Steven B. Ketchum sold 135,205 shares of Amarin stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $4.41, for a total transaction of $596,254.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Joseph T. Kennedy sold 44,857 shares of Amarin stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $3.73, for a total transaction of $167,316.61. The disclosure for this sale can be found here. Insiders have sold a total of 426,720 shares of company stock valued at $1,814,296 in the last ninety days. Company insiders own 3.72% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. State Street Corp grew its holdings in Amarin by 1.3% during the 2nd quarter. State Street Corp now owns 201,995 shares of the biopharmaceutical company’s stock worth $814,000 after acquiring an additional 2,640 shares during the period. Wells Fargo & Company MN boosted its position in shares of Amarin by 15.2% during the second quarter. Wells Fargo & Company MN now owns 37,801 shares of the biopharmaceutical company’s stock worth $152,000 after purchasing an additional 5,000 shares in the last quarter. Dynamic Technology Lab Private Ltd boosted its position in shares of Amarin by 94.2% during the second quarter. Dynamic Technology Lab Private Ltd now owns 87,104 shares of the biopharmaceutical company’s stock worth $351,000 after purchasing an additional 42,246 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Amarin by 32.7% during the fourth quarter. Geode Capital Management LLC now owns 241,576 shares of the biopharmaceutical company’s stock worth $968,000 after purchasing an additional 59,576 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Amarin during the third quarter worth $226,000. 40.26% of the stock is owned by hedge funds and other institutional investors.
Amarin Company Profile
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.